BMAT Regulatory Frameworks & Compliance 4

Question 1

Which of the following best describes the role of a Data Safety Monitoring Board (DSMB) in a clinical trial?

Accepted Answer

It independently reviews accumulating safety and efficacy data and recommends whether to continue, modify, or stop a trial

Answer

A DSMB (also called IDMC) is an independent group of experts that periodically reviews unblinded safety and efficacy data to protect participant welfare and trial integrity.

Question 2

Under FDA regulations, an Investigational New Drug (IND) application must be submitted before which activity?

Accepted Answer

Initiating clinical studies of a new drug in human subjects in the U.S.

Answer

An IND must be in effect before administering an investigational drug to human subjects in the United States, allowing the FDA to review safety data before human exposure.

Question 3

The EU Clinical Trials Regulation (CTR 536/2014) replaced the Clinical Trials Directive and introduced which significant change?

Accepted Answer

A single EU-wide clinical trial authorization via the CTIS portal

Answer

CTR 536/2014 introduced the Clinical Trials Information System (CTIS), enabling sponsors to apply for authorization in multiple EU member states through a single submission.

Question 4

A company discovers that a competitor is using patented biomedical technology without a license. Under U.S. law, the primary legal remedy typically sought is:

Accepted Answer

Initiating patent infringement litigation in federal court seeking injunction and/or damages

Answer

Patent infringement claims in the U.S. are civil matters heard in federal district court, where the patent holder may seek injunctive relief and monetary damages.

Question 5

In the context of pharmaceutical regulation, what is a 'biosimilar'?

Accepted Answer

A biological product highly similar to an already-approved reference biologic with no clinically meaningful differences

Answer

A biosimilar is a biological product that is highly similar to an FDA-approved reference product, with no clinically meaningful differences in safety, purity, or potency.

BMAT - Assessment Practice Test

BMAT - Assessment Practice Test

BMAT Regulatory Frameworks & Compliance 4